# Thymosin Alpha-1 Research: Mechanism, Trials & Evidence > Thymosin Alpha-1 research: the TLR/dendritic-cell mechanism, the hepatitis B, sepsis, COVID-19, HIV and cancer trials, and how strong the evidence is in each setting. Cited. The dendritic-cell mechanism, the key studies setting by setting, and an honest read on how strong the evidence is in each. ## Before the details Thymosin Alpha-1 research spans more than forty years, so it helps to know how to read it. The mechanism is the clearest part: the peptide flips a switch on immune "scout" cells (dendritic cells) that wakes up the rest of the defense, and it does so through danger sensors called Toll-like receptors. The harder part is the clinical evidence, which is uneven by design — different teams tested it in very different diseases. The cleanest results are in chronic hepatitis B, where adding it to antiviral drugs helped more patients clear a marker of the virus. The weakest is in sepsis, where the biggest, most carefully run trial found no benefit at all. COVID-19 results are mixed, and HIV immune-rebuilding studies are small and early. Throughout this page, every number is tied to the study that measured it, in the population and by the route it was actually given. ## Thymosin alpha-1 Thymosin alpha-1 is the 28-amino-acid, N-terminally acetylated thymic polypeptide at the center of this literature. Goldstein and colleagues isolated it from calf thymus (as part of thymosin fraction 5) and determined its complete amino-acid sequence in 1977 [1]. The N-terminal acetylation — a small chemical cap on one end — is essential for activity, and the molecule is cleaved in the body from a 113-amino-acid precursor, prothymosin alpha. The synthetic drug, thymalfasin, is sequence-identical to the natural peptide. Because it has no aromatic residues and no disulfide bonds and is highly acidic, it is a structurally simple, water-soluble peptide that does not bind plasma proteins extensively. ## How Thymosin Alpha-1 works: the dendritic-cell mechanism Thymosin Alpha-1 acts at the interface between innate and adaptive immunity. It signals through Toll-like receptors — notably TLR2 and TLR9 — on dendritic cells and monocytes, driving their maturation, IL-12 production, and antigen presentation, which in turn promotes T-cell maturation and Th1 (cell-mediated) polarization. In a defining mechanistic study, Romani and colleagues showed that Tα1 activates dendritic-cell tryptophan catabolism through indoleamine 2,3-dioxygenase (IDO); IDO activation required TLR9 and type-I-interferon-receptor signalling and produced IL-10 and regulatory T cells [5]. That establishes the dual signature researchers return to repeatedly: Th1 priming held within a tolerogenic, IDO-dependent regulatory frame — restoring effector immunity while damping hyperinflammation. ## Thymalfasin Thymalfasin is the International Nonproprietary Name (INN) for the synthetic, sequence-identical form of Thymosin Alpha-1 used in essentially all clinical trials. A comprehensive review of four decades of literature documents that thymalfasin is approved in more than 35 countries, that the standard single subcutaneous dose studied ranges from 0.8 to 6.4 mg, and that it is usually well tolerated, with the most common adverse effects being local injection-site reactions [4]. It is not approved for marketing in the United States; US availability is limited to investigational and compounding contexts. ## Chronic hepatitis B: the strongest signal The most consistent efficacy comes from chronic viral hepatitis. A meta-analysis of lamivudine plus Tα1 versus lamivudine alone in HBeAg-positive chronic hepatitis B found that combination therapy achieved higher virological response and reduced viral breakthrough [12]. A separate meta-analysis pooling eight trials and 583 patients reported that combination treatment was significantly superior for hepatitis B e-antigen seroconversion — 45.1% versus 15.2% (P<0.00001) — and for virological response, and noted that Tα1 plus entecavir outperformed entecavir monotherapy in cirrhotic patients [13]. These are human endpoints in randomized settings, which is why hepatitis B is graded as the strongest, most reproducible signal in the record. ## Sepsis: from a marginal signal to a null trial Sepsis shows how the evidence titrated down as trial quality rose. The multicentre ETASS randomized controlled trial of 361 patients reported 28-day all-cause mortality of 26.0% with Tα1 versus 35.0% in controls — an absolute reduction of about nine percentage points that did not reach conventional significance (nonstratified P=0.062; log-rank P=0.049), alongside improved monocyte HLA-DR expression [2]. The definitive test followed: the phase-3 TESTS trial enrolled 1,106 adults with sepsis across 22 centres and found no statistically significant difference in 28-day all-cause mortality between Tα1 (23.4%) and placebo (24.1%) — hazard ratio 0.99 (95% CI 0.77–1.27), P=0.93 [3]. This null result in the largest, most rigorous sepsis RCT to date tempers the earlier positive but lower-quality findings. ## Thymosin alpha 1 covid Thymosin alpha 1 COVID-19 evidence is mixed. In a retrospective review of 76 patients with severe COVID-19, Tα1 treatment was associated with significantly reduced mortality (11.11% vs 30.00%, P=0.044); the peptide increased blood T-cell numbers in patients with severe lymphocytopenia and reduced PD-1 and Tim-3 expression on CD8+ T cells, consistent with reversing T-cell exhaustion [6]. Mechanistically, treating SARS-CoV-2-stimulated peripheral blood mononuclear cells with Tα1 in vitro dampened inflammatory activation — reducing TNF-α, IL-6, and IL-8 while increasing IL-10 [14]. The caveat is firm: a 2022 systematic review of roughly 5,300 patients found no statistically significant overall mortality benefit, so the retrospective signals should not be read as established. ## HIV immune reconstitution and transplant support In the immune-reconstitution lens, the studies are real but smaller and often non-blinded. In a pilot study of HIV patients with low CD4 counts on HAART, 12 weeks of Tα1 significantly increased sjTREC levels (a marker of new immune-cell output) in treated patients versus controls, with no serious adverse events; absolute CD4 counts did not differ significantly at 12 weeks [8]. An earlier randomized, non-blinded study combining zidovudine, Tα1, and interferon-alpha reported a substantial increase in CD4+ T-cell number and function over 12 months not seen with zidovudine alone, and called for a controlled double-blind trial [10]. A 2024 study in immunological non-responders living with HIV reported the CD4+ T-cell proportion rising from 17.2% to 29.1% (P<0.001) with reduced PD-1 expression and improved thymic-output markers [15]. After haploidentical stem-cell transplantation, Tα1 was associated with reduced viral reactivation and improved T-cell reconstitution [9]. And in immunosuppressed hemodialysis patients, adding Tα1 to an adjuvanted pandemic H1N1 vaccine improved seroconversion to meet licensing criteria [11]. ## Cancer: an immunomodulatory adjuvant A reappraisal of Thymosin Alpha-1 in cancer therapy positions it as an immunostimulatory adjuvant used in combination with chemo- and immunotherapies in melanoma, hepatocellular carcinoma, and lung cancer — acting through dendritic cells and the adaptive response, potentially helping "turn a cold tumour hot" while restoring mucosal homeostasis to mitigate checkpoint-inhibitor toxicity [7]. This frames Tα1 as a combination-protocol immunomodulator, studied at 1.6 mg subcutaneous twice weekly in such protocols, rather than a standalone anticancer agent. As with every setting on this page, these are study-attributed findings, not established outcomes. --- A titration reading of the Thymosin Alpha-1 (thymalfasin) record — the thymic immunomodulator's strongest hepatitis-B signal logged first, the null phase-3 sepsis trial and the US non-approval held in plain sight, and the molecule kept ruled apart from thymosin beta-4, thymulin, and thymopentin; no clinic behind the rail and nothing here dosed, dispensed, or sold.